Evidence map›Paper›PMID 41233352›Full record

ArticleSignal transduction and targeted therapy2025

Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors.

Chengcheng Zhang, Yubo He, Xiaoye Liu, Jingjing Xie, Meng Fang, Xing Yang, Ryan Huang, Qi Lou, Bufan Li, Ankit Gupta and 5 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chengcheng ZhangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yubo HeDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xiaoye LiuDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jingjing XieDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Meng FangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Xing YangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ryan HuangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Qi LouDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bufan LiDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ankit GuptaCenter for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cheryl LewisHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marc I DiamondCenter for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA.
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA.ORCID 0000-0001-9309-2335
Cheng Cheng ZhangDepartment of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Alec.Zhang@UTSouthwestern.edu.ORCID 0000-0003-4763-3887

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Marcel Bernard Mettlen · 2010 to 2026
$53.7M
ITIM-receptors for cancer treatmentR01CA248736 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, CHENGCHENG · 2020 to 2024
$2.9M
Reprogramming myeloid cells to inhibit cancer developmentR01CA263079 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHENGCHENG ZHANG · 2022 to 2026
$1.9M
Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP15150551Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP190561Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP220032Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) 5P30CA142543Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) Lung Cancer SPORE Development Research ProgramDivision of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) R01CA248736Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) R01CA263079NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA248736NCI NIH HHS R01 CA263079Welch Foundation AU-0042-20030616
6 · The paper itself

Abstract

Amyloid proteins are linked to various diseases; however, their functional roles in immunity and cancer remain unclear. Here, we establish a direct link between oligomeric cystatin C-a cysteine cathepsin inhibitor and a well-characterized amyloidogenic protein-within the tumor microenvironment and the immune inhibitory receptors LILRB2 and LILRB5 on myeloid cells. We demonstrated that human LILRB2 and LILRB5, along with their murine counterpart PIRB, serve as functional receptors for cystatin C oligomers. Engagement of these inhibitory receptors by oligomeric cystatin C enhances the immunosuppressive activity of myeloid cells, leading to T-cell suppression and tumor progression. Deletion of the CST3 gene, which encodes cystatin C, in host mice and tumor cells impaired tumor growth, whereas its overexpression accelerated cancer progression in LILRB2 and LILRB5 transgenic mice. Mechanistically, cystatin C-LILRB2 signaling is driven by both canonical phosphatases and the enhanced TGF-β pathway. Additionally, we identified interactions between LILRB receptors and transthyretin oligomers, another amyloid linked to transthyretin amyloidosis, suggesting a broader paradigm of amyloid-LILRB interactions. Our findings reveal an unexpected role of oligomeric cystatin C in enhancing myeloid cell immunosuppression, expand the functional spectrum of amyloid proteins and underscore the importance of these proteins in immune evasion and cancer development.

Indexed as

Cystatin CMembrane GlycoproteinsMyeloid CellsReceptors, ImmunologicAnimalsHumansMiceMice, TransgenicSignal TransductionTumor MicroenvironmentCST3 protein, humanCystatin CLILRB2 protein, humanMembrane GlycoproteinsPirb protein, mouseReceptors, Immunologic

Identifiers

PMID41233352
PMCPMC12615798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.